Results 171 to 180 of about 4,882 (214)
Some of the next articles are maybe not open access.
Oral idebenone attenuates murine lupus
The Journal of Immunology, 2017Abstract A role for mitochondrial dysfunction has been proposed in the immune dysregulation and organ damage characteristic of systemic lupus erythematous (SLE) disease pathogenesis. We have now examined the role of drugs that may improve mitochondrial function in SLE symptomatology in murine models of lupus.
Luz P Blanco +6 more
openaire +1 more source
Stability study of oral pediatric idebenone suspensions
Pharmaceutical Development and Technology, 2016Adapted forms for administration to infants are limited. The proposed study was performed to propose oral liquid formulations of idebenone in Ora-Plus and either Ora-Sweet or Ora-Sweet SF, Ora-Blend, Ora-Blend SF and Inorpha. Each formulation was stored in 30 ml amber glass bottle at 5 or 25 °C for 90 days.
Joël, Schlatter +6 more
openaire +2 more sources
Idebenone for Leber's hereditary optic neuropathy
Drugs of Today, 2016Idebenone is a rapidly absorbed, safe and well-tolerated drug and is currently the only clinically proven treatment option for Leber's hereditary optic neuropathy (LHON) patients. Idebenone (Raxone®) is approved by the European Medicines Agency for the treatment of LHON and has been available on the European market since 2015. Due to its molecular mode
openaire +2 more sources
Inhibition of brain mitochondrial swelling by idebenone
Archives of Gerontology and Geriatrics, 1989The effects of idebenone on the swelling of rat brain mitochondria were studied. When FeCl3 was added to a mitochondrial suspension, a pronounced mitochondrial swelling occurred accompanied by the production of lipid peroxide; the two phenomena were closely correlated (r = 0.96, p less than 0.01).
M, Suno, A, Nagaoka
openaire +2 more sources
Friedreich's Ataxia: Idebenone Treatment in Early Stage Patients
Neuropediatrics, 2002Antioxidant therapy has been applied to Friedreich's ataxia patients. We assessed the effect of idebenone treatment in patients with Friedreich's ataxia.open-label trial. Nine Friedreich's ataxia patients (age range 11 - 19 years) were treated with idebenone (5 mg/kg/day).
Artuch R +6 more
openaire +3 more sources
Idebenone treatment in Friedreich’s ataxia
Neurology, 2003The authors report 1-year prospective data on eight patients with Friedreich ataxia. Idebenone did not halt the progression of ataxia. At the end of therapy, cardiac ultrasound demonstrated significant reduction of cardiac hypertrophy in six of eight patients.
BUYSE G +9 more
openaire +3 more sources
Protective effect of idebenone against hypoxia in mice
Archives of Gerontology and Geriatrics, 1989The effects of idebenone on survival time of mice subjected to hypoxia induced by N2 and CO2 inhalation and KCN injection were studied. Idebenone (10, 20, 50 and 100 mg/kg, i.p.) prolonged the survival time of mice exposed to a hypoxic condition (98% N2, 2% O2) in a dose-dependent manner: significant prolongations were observed at doses higher than 20 ...
Y, Kiyota, M, Miyamoto, A, Nagaoka
openaire +2 more sources
A controlled trial of idebenone in Huntington's disease
Movement Disorders, 1996AbstractOne hundred patients with clinically diagnosed Huntington's disease (HD) were randomized to either idebenone, an antioxidant and enhancer of oxidative metabolism, or placebo, in a 1‐year, double‐blind, parallel‐group study aimed at slowing the rate of progression of the disease. Ninety‐one patients completed the study. There were no significant
N G, Ranen +9 more
openaire +2 more sources
Steady-state pharmacokinetics of idebenone in healthy volunteers
Archives of Gerontology and Geriatrics, 1992An open study was conducted with 12 healthy male Caucasian volunteers to determine the single dose and steady-state pharmacokinetics in plasma after a total daily dose of 90 mg of idebenone administered as 45 mg twice daily for 10 consecutive days.
J, Boni +4 more
openaire +2 more sources